DARE
Income statement / Annual
Last year (2023), Daré Bioscience, Inc.'s total revenue was $2.81 M,
a decrease of 71.92% from the previous year.
In 2023, Daré Bioscience, Inc.'s net income was -$30.16 M.
See Daré Bioscience, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$2.81 M
|
$10.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$766,000.00
|
$0.00
|
$80,000.00
|
Cost of Revenue |
$38,363.00 |
$47,617.00 |
$26,413.00 |
$43,227.00 |
$11,137.00 |
$2,440.00 |
$0.00 |
$400,000.00 |
$192,000.00 |
$0.00 |
Gross Profit |
$2.77 M |
$9.95 M |
-$26,413.00 |
-$43,227.00 |
-$11,137.00 |
-$2,440.00 |
$0.00 |
$366,000.00 |
-$192,000.00 |
$80,000.00 |
Gross Profit Ratio |
0.99 |
1 |
0 |
0 |
0 |
0 |
0 |
0.48 |
0 |
1 |
Research and Development
Expenses |
$21.54 M
|
$30.04 M
|
$30.62 M
|
$20.77 M
|
$8.55 M
|
$6.41 M
|
$984,749.00
|
$27.57 M
|
$25.95 M
|
$11.77 M
|
General & Administrative
Expenses |
$12.11 M
|
$11.24 M
|
$8.45 M
|
$6.63 M
|
$5.80 M
|
$5.28 M
|
$2.70 M
|
$10.36 M
|
$11.22 M
|
$8.59 M
|
Selling & Marketing
Expenses |
-$38,363.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$12.07 M
|
$11.24 M
|
$8.45 M
|
$6.63 M
|
$5.80 M
|
$5.28 M
|
$2.70 M
|
$10.36 M
|
$11.22 M
|
$8.59 M
|
Other Expenses |
$778,489.00 |
$100,000.00 |
$2,520.00 |
$1,514.00 |
$81,050.00 |
$143,497.00 |
$7.49 B |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$33.61 M |
$41.39 M |
$39.07 M |
$27.40 M |
$14.34 M |
$11.69 M |
$3.69 M |
$37.92 M |
$37.17 M |
$20.36 M |
Cost And Expenses |
$33.65 M |
$41.39 M |
$39.07 M |
$27.40 M |
$14.34 M |
$11.69 M |
$3.69 M |
$37.92 M |
$37.17 M |
$20.36 M |
Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$86,000.00 |
$10,000.00 |
$9,000.00 |
Interest Expense |
$0.00 |
-$437.75 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$322,629.00 |
$2.24 M |
$2.43 M |
$1.08 M |
Depreciation &
Amortization |
$38,363.00
|
$47,617.00
|
$26,413.00
|
$43,227.00
|
$11,137.00
|
$2,440.00
|
$2.73 M
|
$261,000.00
|
$192,000.00
|
$126,000.00
|
EBITDA |
-$30.80 M
|
-$31.39 M
|
-$39.41 M
|
-$27.36 M
|
-$14.33 M
|
-$6.50 M
|
-$3.69 M
|
-$36.81 M
|
-$36.97 M
|
-$20.14 M
|
EBITDA Ratio |
-10.97 |
-3.14 |
0 |
0 |
0 |
0 |
0 |
-48.05 |
0 |
-251.8 |
Operating Income Ratio
|
-10.98
|
-3.14
|
0
|
0
|
0
|
0
|
0
|
-48.5
|
0
|
-253.49
|
Total Other
Income/Expenses Net |
$678,489.00
|
$437,750.00
|
$372,407.00
|
$1,514.00
|
$81,050.00
|
$143,497.00
|
-$7.49 M
|
-$2.15 M
|
-$2.42 M
|
-$1.99 M
|
Income Before Tax |
-$30.16 M |
-$30.95 M |
-$38.70 M |
-$27.40 M |
-$14.26 M |
-$16.74 M |
-$11.50 M |
-$39.31 M |
-$39.59 M |
-$23.34 M |
Income Before Tax Ratio
|
-10.74
|
-3.09
|
0
|
0
|
0
|
0
|
0
|
-51.31
|
0
|
-291.78
|
Income Tax Expense |
-$3.00 |
-$437.75 M |
-$369,887.00 |
-$163,070.00 |
-$160,723.00 |
$10.23 M |
-$7.17 M |
$86,000.00 |
$10,000.00 |
$1.08 M |
Net Income |
-$30.16 M |
-$30.95 M |
-$38.33 M |
-$27.40 M |
-$14.26 M |
-$26.97 M |
-$11.50 M |
-$39.31 M |
-$39.59 M |
-$23.34 M |
Net Income Ratio |
-10.74 |
-3.09 |
0 |
0 |
0 |
0 |
0 |
-51.31 |
0 |
-291.78 |
EPS |
-4.15 |
-4.39 |
-7.52 |
-10.93 |
-10.99 |
-30.16 |
-3.56 |
-14.18 |
-15.57 |
-16.04 |
EPS Diluted |
-4.15 |
-4.39 |
-7.52 |
-10.93 |
-10.99 |
-30.16 |
-3.56 |
-14.18 |
-15.57 |
-16.04 |
Weighted Average Shares
Out |
$7.28 M
|
$7.05 M
|
$5.10 M
|
$2.51 M
|
$1.30 M
|
$894,367.00
|
$269,356.00
|
$69,206.00
|
$2.54 M
|
$1.45 M
|
Weighted Average Shares
Out Diluted |
$7.28 M
|
$7.05 M
|
$5.10 M
|
$2.51 M
|
$1.30 M
|
$894,368.00
|
$269,356.00
|
$69,583.00
|
$0.00
|
$1.45 M
|
Link |
|
|
|
|
|
|
|
|
|
|